Literature DB >> 19879187

Congenital cytomegalovirus: Public health action towards awareness, prevention, and treatment.

Gail J Demmler-Harrison1.   

Abstract

Key awareness issues surrounding congenital CMV infection are outlined and discussed to provide inspirational motivation for many diverse groups who may have the same goal of reducing congenital CMV disease. To this end, steps for public health action towards awareness, prevention and treatment are outlined. These steps include recommendations for universal screening for all newborns for congenital CMV infection at birth to further define the public health impact and facilitate early diagnosis and treatment of newborns, routine prenatal screening of all pregnant women for the presence of CMV antibody to identify women at risk who may benefit most from preventive behavioral interventions as well as to facilitate prenatal diagnosis and therapies, and grass roots efforts to promote CMV awareness in the community.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19879187     DOI: 10.1016/j.jcv.2009.10.007

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  16 in total

1.  Cytomegalovirus survival on common environmental surfaces: opportunities for viral transmission.

Authors:  Jennifer D Stowell; Daniela Forlin-Passoni; Erica Din; Kay Radford; Denise Brown; Audrey White; Sheri L Bate; Sheila C Dollard; Stephanie R Bialek; Michael J Cannon; D Scott Schmid
Journal:  J Infect Dis       Date:  2011-11-23       Impact factor: 5.226

2.  Could therapeutic vaccination of cytomegalovirus-seropositive persons prevent reinfection and congenital virus transmission?

Authors:  Mark R Schleiss
Journal:  J Infect Dis       Date:  2011-06-01       Impact factor: 5.226

Review 3.  Review of cytomegalovirus shedding in bodily fluids and relevance to congenital cytomegalovirus infection.

Authors:  Michael J Cannon; Terri B Hyde; D Scott Schmid
Journal:  Rev Med Virol       Date:  2011-06-15       Impact factor: 6.989

Review 4.  Universal newborn screening for congenital CMV infection: what is the evidence of potential benefit?

Authors:  Michael J Cannon; Paul D Griffiths; Van Aston; William D Rawlinson
Journal:  Rev Med Virol       Date:  2014-04-24       Impact factor: 6.989

Review 5.  The "silent" global burden of congenital cytomegalovirus.

Authors:  Sheetal Manicklal; Vincent C Emery; Tiziana Lazzarotto; Suresh B Boppana; Ravindra K Gupta
Journal:  Clin Microbiol Rev       Date:  2013-01       Impact factor: 26.132

6.  Impact of a cytomegalovirus kinase inhibitor on infection and neuronal progenitor cell differentiation.

Authors:  Tarin M Bigley; Jered V McGivern; Allison D Ebert; Scott S Terhune
Journal:  Antiviral Res       Date:  2016-02-11       Impact factor: 5.970

7.  Awareness of and behaviors related to child-to-mother transmission of cytomegalovirus.

Authors:  Michael J Cannon; Kyresa Westbrook; Denise Levis; Mark R Schleiss; Rosemary Thackeray; Robert F Pass
Journal:  Prev Med       Date:  2012-03-21       Impact factor: 4.018

8.  Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response.

Authors:  Xinle Cui; Zhouhong Cao; Shuishu Wang; Ronzo B Lee; Xiao Wang; Haruhiko Murata; Stuart P Adler; Michael A McVoy; Clifford M Snapper
Journal:  Vaccine       Date:  2018-08-03       Impact factor: 3.641

9.  The Serological Evidence of Cytomegalovirus Infection as a Potent Aetiological Factor for Cleft Lip/Palate, Mental Retardation and Deafness.

Authors:  D V Divya; Madu Ghana Shyam Prasad; Ambati Naga Radhakrishna; S Pavani Reddy; K Pratyusha; K V K Santosh Kumar; R V Sandeep
Journal:  J Clin Diagn Res       Date:  2017-06-01

10.  In vitro combination of anti-cytomegalovirus compounds acting through different targets: role of the slope parameter and insights into mechanisms of Action.

Authors:  Hongyi Cai; Arun Kapoor; Ran He; Rajkumar Venkatadri; Michael Forman; Gary H Posner; Ravit Arav-Boger
Journal:  Antimicrob Agents Chemother       Date:  2013-11-25       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.